期刊文献+

利拉鲁肽治疗初诊肥胖2型糖尿病患者的效果 被引量:2

Effect of Liraglutide on newly diagnosed obese patients with type 2 diabetes mellitus
下载PDF
导出
摘要 目的研究利拉鲁肽(LRG)治疗初诊肥胖2型糖尿病(T2DM)的效果。方法选取2020年5月至2021年5月哈尔滨市第一医院内分泌科的84例初诊肥胖T2DM患者作为研究对象,采用随机数字表法将其分为对照组和观察组,每组各42例。对照组患者采用二甲双胍治疗,观察组患者加用LRG治疗。比较两组患者的体重指数(BMI)及血糖水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)]、纤维细胞生长因子-21(FGF-21)水平、微炎症指标[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、血清淀粉样蛋白A(ASAA)]、氧化应激指标[丙二醇(MDA)、脂质过氧化氢(LPO)、谷胱甘肽过氧化物酶(GSH-Px)]、不良反应发生情况。结果观察组治疗后的BMI、FPG、2 h PG低于对照组,差异有统计学意义(P<0.05)。观察组治疗后的FGF-21水平低于对照组,差异有统计学意义(P<0.05);观察组治疗后的IL-6、TNF-α、ASAA低于对照组,差异有统计学意义(P<0.05);观察组治疗后的MDA、LPO低于对照组,GSH-Px高于对照组,差异有统计学意义(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论LRG治疗能够改善初诊肥胖T2DM患者的体重指数及血糖水平,降低FGF-21水平,调节微炎症及氧化应激指标,值得应用。 Objective To study the effect of Liraglutide(LRG)on newly diagnosed obese type 2 diabetes mellitus(T2DM).Methods A total of 84 newly diagnosed obese T2DM patients in the Department of Endocrinology of Harbin First Hospital from May 2020 to May 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,with 42 cases in each group.Patients in the control group were treated with metformin,while patients in the observation group were treated with LRG.The body mass index(BMI)and blood glucose levels(fasting blood glucose[FPG],2 h postprandial blood glucose[2 h PG]),fibrocyte growth factor-21(FGF-21)level,microinflammatory indicators(interleukin-6[IL-6],tumor necrosis factor-α[TNF-α],serum amyloid A[ASAA]),oxidative stress indicators(propylene glycol[MDA],lipid hydrogen peroxide[LPO],glutathione peroxidase[GSH-Px])and the occurrence of adverse reactions were compared between the two groups.Results The BMI,FPG and 2 h PG of the observation group after treatment were lower than those of the control group,and the differences were statistically significant(P<0.05).The level of FGF-21 in the observation group was lower than that in the control group after treatment,and the difference was statistically significant(P<0.05).The IL-6,TNF-αand ASAA of the observation group after treatment were lower than those of the control group,and the differences were statistically significant(P<0.05).After treatment,MDA and LPO in the observation group were lower than those in the control group,and GSH-Px was higher than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion LRG treatment can improve the BMI and blood glucose level of newly diagnosed obese patients with T2DM,reduce the level of FGF-21,and regulate the indexes related to micro-inflammation and oxidative stress,which is worthy of application.
作者 梁桂敏 苏冬雪 邵宁 陈萍 王莹 马晶 LIANG Guimin;SU Dongxue;SHAO Ning;CHEN Ping;WANG Ying;MA Jing(Department of Endocrinology,Harbin First Hospital,Heilongjiang Province,Harbin 150010,China)
出处 《中国当代医药》 CAS 2022年第32期68-71,共4页 China Modern Medicine
关键词 利拉鲁肽 肥胖2型糖尿病 成纤维细胞生长因子-21 二甲双胍 Liraglutide Obese with type 2 diabetes mellitus Fibroblast growth factor-21 Metformin
  • 引文网络
  • 相关文献

参考文献21

二级参考文献172

共引文献467

同被引文献36

二级引证文献3

;
使用帮助 返回顶部